Search

Simple Summary: This study evaluated the molecular prevalence and genetic characterization of equine EHV-1/4 in equids populations in Morocco. Among 154 samples analyzed, 27% tested positive for EHV-4, while only 1.94% were positive for EHV-1. Virus isolation was unsuccessful in EHV-4-positive samples but EHV-1 was isolated from a positive donkey sample. Phylogenetic and molecular analyses reclassified the EHV-1 isolate from the donkey as EHV-8, while the EHV-1 isolate from aborted fetal tissue was identified as clade 1 EHV-1. This study confirms the active circulation of EHV-1 and EHV-4 in Moroccan equines, reports the first detection of EHV-8 in a donkey in Africa, and highlights EHV-4′s prevalence and its association with respiratory disorders, abortions, and neonatal deaths. This study aimed to investigate the molecular prevalence and genetic characterization of EHV-1 and EHV-4 in equid populations in Morocco. A total of 154 equids (114 horses, 9 donkeys, and 31 mules) were sampled, with nasal swabs and tissue samples subjected to multiplex real-time PCR for the detection of EHV-1 and EHV-4. Additionally, an isolate from the tissue of an aborted horse fetus was included in the analysis. A subset of EHV-positive samples underwent virus isolation followed by whole-genome sequencing. PCR assays revealed that 42 samples (27%) tested positive for EHV-4, while only 3 samples (1.94%) were positive for EHV-1. Attempts to isolate the virus from EHV-4-positive samples were unsuccessful. However, virus isolation was successful in an EHV-1-positive nasopharyngeal sample from a donkey. Phylogenetic and molecular characterization reclassified the EHV-1 isolated from the donkey as an EHV-8. Meanwhile, the EHV-1 isolated from the aborted fetal tissue was classified as a clade 1 EHV-1 virus. This study is the first to report the molecular prevalence and genetic characterization of EHV-1 and EHV-4 in equid populations in Morocco, providing valuable insights into the distribution and genetic diversity of these viruses in the region. [ABSTRACT FROM AUTHOR]

The study conducted in Morocco focused on addressing the challenges posed by canine parvovirus (CPV-2) through comprehensive research, vaccine development, and efficacy assessment. Through real-time PCR screening and genotyping, CPV-2 variants were identified circulating in the region. An inactivated vaccine, derived from a CPV-2 strain isolated from a symptomatic dog, was produced and evaluated for safety and efficacy. The vaccine, from the strain named "CaPV M/3-2022", demonstrated safety in vaccinated puppies, with no adverse reactions observed during the trial period. Efficacy trials showed that vaccinated puppies remained healthy and exhibited lower viral excretion post-challenge compared to unvaccinated controls. These results indicate that the vaccine effectively protects against illness related to CPV-2 and reduces viral shedding. The study provides valuable insights into CPV-2 epidemiology in Morocco, offers a promising vaccine solution, and underscores the importance of vaccination in controlling CPV-2 outbreaks and protecting canine health. [ABSTRACT FROM AUTHOR]